Chemotherapy and Radiotherapy for Brain Metastases
Author Information
Author(s): Carsten Nieder, Anca L. Grosu, Sabrina Astner, Reinhard Thamm, Michael Molls
Primary Institution: Department of Radiation Oncology, Klinikum rechts der Isar der Technischen Universität München
Hypothesis
Can chemotherapy combined with whole-brain radiotherapy improve outcomes for patients with brain metastases?
Conclusion
Chemotherapy combined with whole-brain radiotherapy did not improve survival, but may affect neurologic progression-free survival and quality of life.
Supporting Evidence
- Response rates with chemotherapy alone were mostly in the order of 20–40%.
- Median survival for patients receiving chemotherapy was between 3 to 10 months.
- Most patients with brain metastases die from extracranial progression rather than neurological causes.
Takeaway
This study looked at how chemotherapy and radiation work together for patients with brain tumors. It found that while they don't help people live longer, they might help them feel better for a while.
Methodology
A systematic literature review comparing clinical trials of chemotherapy and combined radio- and chemotherapy for brain metastases.
Potential Biases
Selection bias may affect the comparison of treatment outcomes.
Limitations
The study is based on small and heterogeneous patient groups, and many trials lacked sufficient power.
Participant Demographics
Patients with brain metastases from various solid tumors, including melanoma, breast cancer, lung cancer, and ovarian cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website